NASDAQ:ARGX - argenx Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding argenx SE - Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $161.10 -0.07 (-0.04 %) (As of 02/21/2020 04:00 PM ET) Add Compare Today's Range$160.80Now: $161.10▼$162.8850-Day Range$143.32MA: $154.85▼$165.2352-Week Range$106.49Now: $161.10▼$169.50Volume209,502 shsAverage Volume114,029 shsMarket Capitalization$6.14 billionP/E RatioN/ADividend YieldN/ABeta1.3 ProfileAnalyst RatingsAdvanced ChartFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARGX Previous Symbol CUSIPN/A CIK1697862 Webhttp://www.argenx.com/ Phone329-310-3400Debt Debt-to-Equity Ratio0.01 Current Ratio9.37 Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$25.37 million Price / Sales242.00 Cash FlowN/A Price / Cash FlowN/A Book Value$17.67 per share Price / Book9.12Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees103 Outstanding Shares38,110,000Market Cap$6.14 billion Next Earnings Date3/24/2020 (Estimated) OptionableOptionable Receive ARGX News and Ratings via Email Sign-up to receive the latest news and ratings for ARGX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ARGX Rates by TradingView argenx (NASDAQ:ARGX) Frequently Asked Questions What is argenx's stock symbol? argenx trades on the NASDAQ under the ticker symbol "ARGX." When is argenx's next earnings date? argenx is scheduled to release their next quarterly earnings announcement on Tuesday, March 24th 2020. View Earnings Estimates for argenx. What price target have analysts set for ARGX? 14 brokerages have issued 12 month price objectives for argenx's stock. Their forecasts range from $125.00 to $194.00. On average, they expect argenx's share price to reach $168.92 in the next year. This suggests a possible upside of 4.9% from the stock's current price. View Analyst Price Targets for argenx. What is the consensus analysts' recommendation for argenx? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for argenx in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for argenx. Has argenx been receiving favorable news coverage? Media stories about ARGX stock have been trending somewhat negative recently, InfoTrie reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. argenx earned a news sentiment score of -1.9 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for argenx. Who are some of argenx's key competitors? Some companies that are related to argenx include Seattle Genetics (SGEN), NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), Qiagen (QGEN), BIO-TECHNE (TECH), BioNTech (BNTX), Moderna (MRNA), Repligen (RGEN), Acceleron Pharma (XLRN), China Biologic Products (CBPO), bluebird bio (BLUE), Spark Therapeutics (ONCE), Adaptive Biotechnologies (ADPT), Ablynx (ABLYF) and Crispr Therapeutics (CRSP). What other stocks do shareholders of argenx own? Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include GALAPAGOS NV/S (GLPG), AcelRx Pharmaceuticals (ACRX), Neurocrine Biosciences (NBIX), Netflix (NFLX), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Intellia Therapeutics (NTLA), Amarin (AMRN), Exelixis (EXEL) and Fate Therapeutics (FATE). Who are argenx's key executives? argenx's management team includes the folowing people: Mr. Tim Van Hauwermeiren, CEO & Exec. Director (Age 47)Mr. Eric Castaldi, Chief Financial Officer (Age 55)Prof. Hans de Haard, Chief Scientific Officer (Age 59)Mr. Dirk Marcel Leon Beeusaert, Gen. Counsel (Age 55)Dr. Torsten Dreier, Chief Devel. Officer (Age 55) When did argenx IPO? (ARGX) raised $65 million in an IPO on Thursday, May 18th 2017. The company issued 3,600,000 shares at a price of $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are argenx's major shareholders? argenx's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (11.14%), Artisan Partners Limited Partnership (3.46%), Franklin Resources Inc. (1.64%), Capital World Investors (1.51%), Eaton Vance Management (1.08%) and Janus Henderson Group PLC (0.88%). Which institutional investors are selling argenx stock? ARGX stock was sold by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Citigroup Inc., Pictet Asset Management Ltd., Driehaus Capital Management LLC, Lord Abbett & CO. LLC, AXA, Credit Suisse AG and Barclays PLC. Which institutional investors are buying argenx stock? ARGX stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Jane Street Group LLC, Capital World Investors, Fiera Capital Corp, Franklin Resources Inc., Fairmount Funds Management LLC, Eventide Asset Management LLC and Jennison Associates LLC. How do I buy shares of argenx? Shares of ARGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is argenx's stock price today? One share of ARGX stock can currently be purchased for approximately $161.10. How big of a company is argenx? argenx has a market capitalization of $6.14 billion and generates $25.37 million in revenue each year. The company earns $-78,700,000.00 in net income (profit) each year or ($2.35) on an earnings per share basis. argenx employs 103 workers across the globe.View Additional Information About argenx. What is argenx's official website? The official website for argenx is http://www.argenx.com/. How can I contact argenx? argenx's mailing address is Willemstraat 5, Breda P7, 4811 AH. The company can be reached via phone at 329-310-3400 or via email at [email protected] MarketBeat Community Rating for argenx (NASDAQ ARGX)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 465 (Vote Outperform)Underperform Votes: 467 (Vote Underperform)Total Votes: 932MarketBeat's community ratings are surveys of what our community members think about argenx and other stocks. Vote "Outperform" if you believe ARGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARGX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/22/2020 by MarketBeat.com StaffFeatured Article: Technical Indicators - What is a Golden Cross?
